Kate Moodie
The University of Melbourne(AU)Peter MacCallum Cancer Centre(AU)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, PI3K/AKT/mTOR signaling in cancer, Cancer Genomics and Diagnostics
Most-Cited Works
- → PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial(2022)242 cited
- → Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial(2023)178 cited
- → A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer(2019)144 cited
- → Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT(2010)128 cited
- → FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy(2011)65 cited
- → Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study(2022)52 cited
- → The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification(2014)47 cited
- → A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment(2016)32 cited
- → Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution(2017)30 cited
- → Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial(2025)19 cited